Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.32 |
| ▸ | LIPC | P11150 | 1/20 | 0.32 |
| ▸ | LSS | P48449 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.31 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21106934 | 0.86 | CHRNB2 (0.34) | HSD17B10LIPGLIPCLSSGBA1 | |
| SCHEMBL25122639 | 0.85 | PIK3CD (0.37) | LIPGEPHX2 | |
| SCHEMBL25883099 | 0.84 | HRH2 (0.38) | LIPGLIPC | |
| SCHEMBL24672686 | 0.84 | LIPG (0.33) | HSD17B10LIPGLIPCLSSGBA1 | |
| SCHEMBL25922657 | 0.81 | REN (0.36) | LIPGLIPCEPHX2NAMPT | |
| SCHEMBL25730022 | 0.81 | REN (0.36) | LIPGLIPC | |
| SCHEMBL24672696 | 0.80 | PIK3CD (0.41) | HSD17B10LSSGBA1EPHX2KMT2A | |
| SCHEMBL23560455 | 0.78 | CHRNB2 (0.37) | HSD17B10LSSGBA1KMT2ANAMPT | |
| SCHEMBL23568087 | 0.78 | ITGB3 (0.36) | HSD17B10LSSGBA1NAMPT | |
| SCHEMBL25728303 | 0.77 | EPHX2 (0.39) | HSD17B10LSSEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11318205-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | HSD17B10 2107/4885LIPG 2233/4885LIPC 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.